PNEUMOCYSITIS CARINII INFECTION THERAPIES--PRECLIN EVAL

本合同的总体目标是促进发现和 开发具有治疗和预防潜力的疗法 卡氏肺孢子虫肺炎的发病率 本合同的预期性能是定量评估 对卡氏肺孢子虫肺炎有效的治疗剂 在标准化的、经验证的小鼠模型测试系统中，包括 在初级小鼠模型中联合治疗的评价， 在初级小鼠模型中预防方案中的药物评价， 以及在大鼠模型中评价治疗疗法。 治疗 将以标准化的、可重复的方法评价试剂的活性。 并验证了体外（培养）试验系统， 有机体

The overall objective of this contract is to facilitate discovery and development of therapies with potential for treatment and prophylaxis of Pneumocystis carinii pneumonia in people with AIDS. The expected performance of this contract is to quantitatively evaluate therapeutic agents for efficacy against Pneumocystis carinii pneumonia in a standardized, validated mouse model test system, to include evaluation of therapies in combination in the primary mouse model, drug evaluations in prophylaxis protocols in the primary mouse model, and evaluation of treatment therapies in a rat model. Therapeutic agents will be evaluated for activity in a standardized, reproducible and validated in vitro (culture) test system which employs intact organisms.